Italfarmaco Group
↗Milan, Italy
Italfarmaco Group is a private Italian multinational pharmaceutical and fine chemical company founded in 1938. Headquartered in Milan, the group operates globally with a strong presence in Europe, the Americas, and Asia, specializing in high-therapeutic content products for rare diseases, cardiovascular health, women's health, and oncology.
The company is a leader in the development of epigenetic therapies, particularly histone deacetylase (HDAC) inhibitors. Its flagship product, Duvyzat (givinostat), is the first non-steroidal drug approved for Duchenne Muscular Dystrophy (DMD). Italfarmaco also operates a significant fine chemicals business through its subsidiary Chemi S.p.A., which manufactures active pharmaceutical ingredients (APIs) and complex molecules for global markets.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Rare Disease Therapeutics & Fine Chemicals
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1B+
Founded:1938
Ownership:private
Status:operating
FUNDING
Stage:Late Stage
Total Raised:$1.1B+
Investors:European Union (Grant), De Santis Family (Private Ownership)
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved (FDA/EMA)
Modalities:Small molecule, Peptides, Monoclonal antibodies, Biosimilars
Active Trials:12
Trial Phases:Phase 1: 4 | Phase 2: 5 | Phase 3: 3
FDA Approvals:3
EMA Approvals:2
CORPORATE STRUCTURE
Parent Company:Italfarmaco Holding S.p.A.
Subsidiaries:Chemi S.p.A., ITF Therapeutics LLC, Lacer S.A., Lifepharma
Key Partnerships:Iktos (AI for drug discovery), JCR Pharmaceuticals (Japan commercialization), Istituto Ronzoni (BioSpecNet consortium)
COMPETITION
Position:Leader
Competitors:Sarepta Therapeutics, PTC Therapeutics, Recordati, Zambon, Dompé
LEADERSHIP
Key Executives:
Francesco Di Marco - CEO (Effective Jan 2026)
Francesco De Santis - Chairman
Scientific Founders:Gastone De Santis
Board Members:Francesco De Santis, Francesco Di Marco, Carlos Barallobre
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Italfarmaco Group. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.